Latest Innovation News

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Earlypay Limited reported a 24% rise in underlying net profit after tax for FY25, driven by robust growth in equipment finance and improved credit performance, while declaring a fully franked dividend and forecasting further earnings growth in FY26.

Earlypay Ltd reported a 31% rise in statutory net profit after tax for FY25, driven by growth in equipment finance despite declines in invoice and trade finance. The company declared a fully franked final dividend of 0.65 cents per share and outlined plans to expand its lending portfolios and streamline technology.

Fluence Corporation has agreed with its revolving lenders, who are also board members, to convert $1.8 million of accrued interest into shares, pending shareholder approval. This move aims to preserve cash and enhance operational flexibility as the company pursues growth.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

Scentre Group reported a robust half-year result with profit after tax surging to $782.2 million and Funds From Operations rising 3.2%, underpinned by strong retail sales and near-record occupancy. The Group also advanced a $4 billion development pipeline and sold a 25% stake in Westfield Chermside, maintaining management control.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.